NRX Pharmaceuticals, Inc.
NRXPNasdaq
$4.27
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↑ +41.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$2.3M
Net Income (TTM)
-$24.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-746.6%
Net Margin
-1070.2%
ROE
177.6%
ROIC
—
Debt / Equity
—
Net Cash
$6.7M
Return 1Y
+40.9%
Company profile
NRX Pharmaceuticals, Inc. develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure.
- CEO
- Stephen H. Willard
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Delaware
- Website
- nrxpharma.com
Earnings
NRXP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.1M—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $1.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$51.4M | -$115.8M | -$44.3M | -$27.8M | -$18.5M | -$16.2M |
| Net income | -$51.8M | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M |
| Diluted EPS | -$1.51 | -$1.98 | -$0.60 | — | — | — |
| Operating cash flow | -$2.3M | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -1324.4% |
| Net margin | — | — | — | — | — | -2336.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | — | $0.00 | $0.00 | $242,000.00 | $983,000.00 | $1.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.0M | -$3.0M | -$2.4M | -$3.8M | -$3.7M | -$4.0M | -$4.6M | -$4.7M |
| Net income | -$7.9M | -$1.6M | -$9.1M | -$5.5M | -$17.6M | -$5.9M | $361,000.00 | -$1.4M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$2.6M | -$2.3M | -$2.1M | -$3.5M | -$4.0M | -$2.9M | -$3.7M | -$4.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -1662.8% | -470.3% | -444.0% |
| Net margin | — | — | — | — | — | -2433.9% | 36.7% | -133.9% |
Company news
Jun 25, 2026
Jun 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.